ESSA Pharma Inc.
essapharma.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Aug 13, 2025. Its latest SEC filing is a EFFECT from Nov 14, 2025.
10-Q for Q3 FY2025, filed Aug 13, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Developed investigational therapies for prostate cancer, including compounds intended to block androgen-receptor signaling, for patients with prostate cancer.
10-K for FY2024, filed Dec 17, 2024ESSA is a clinical stage pharmaceutical company that, prior to the discontinuation of its clinical trials and preclinical and other…View ↗
The Company believed its latest series of investigational compounds, including its previously planned product candidate masofaniten…View ↗
The Company believed that the transcription inhibition mechanism of its preclinical compounds was unique and had the potential advantage of…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Aug 13, 2025
−$4MView ↗
- ▼ −45% (Loss)
- vs −$7.2M in Q3 FY2024
-
Oct 9, 2025
XenoTherapeutics acquired ESSA, changing control and delisting its shares
Each share converted into US$0.1242 plus a contingent value right worth up to approximately US$0.14 per CVR.
Sources
8-K, filed Oct 9, 2025
Subject to the terms and conditions set forth in the Agreement and the Arrangement, on October 9, 2025, each Share outstanding immediately…View ↗
Who Did They Compete With?
Competes with Astellas, Pfizer, Johnson & Johnson, Sun Pharma, Valeant, Sanofi, Bayer, Merck, AstraZeneca, Clovis Oncology, Novartis, and Arvinas
10-K for FY2024, filed Dec 17, 2024 GENERIC/PROGRAMNAME BRAND NAME COMPANY NAME(S) STAGE Enzalutamide Xtandi Astellas and Pfizer Marketed Abiraterone…View ↗
Loading...
